Gynecologic Oncology

Gynecol Oncol · ISSN (print) 0090-8258 · ISSN (e) 1095-6859 · 338 papers in corpus
other 2026
doi:10.1016/j.ygyno.2026.05.029 ·PMID:42229041
meta-analysis 2026
doi:10.1016/j.ygyno.2026.05.004 ·PMID:42119308

OBJECTIVE: To critically evaluate the evidence linking endometriosis to ovarian cancer, with particular focus on endometrioid and clear cell histologic subtypes, and to inform risk stratification and patient counseling. METHODS: A systemat…

observational 2026
doi:10.1016/j.ygyno.2026.05.020 ·PMID:42217257

OBJECTIVE: To identify clinicopathologic predictors of concurrent endometrial carcinoma (EC) and need for lymph node assessment at time of hysterectomy for atypical endometrial hyperplasia (AEH) in a minority-enriched population. METHODS: …

observational 2026
doi:10.1016/j.ygyno.2026.04.017 ·PMID:42102522

ObjectiveTo explore uptake of risk-reducing gynecologic surgery in a diverse patient population with Lynch syndrome.MethodsChart reviews of women with Lynch syndrome were conducted at a safety-net hospital and university medical center, inc…

2025
doi:10.1016/j.ygyno.2025.04.520
observational 2025
doi:10.1016/j.ygyno.2025.02.017 ·PMID:40054046

BACKGROUND/OBJECTIVE: Adenomyosis is a benign uterine disorder characterized by an inflammatory and hyperestrogenic state. Its association with endometrial cancer (EC) remains controversial. This study aimed to investigate the correlation b…

other 2025
doi:10.1016/j.ygyno.2025.04.516 ·PMID:40222070

OBJECTIVE(S): We aimed to assess the feasibility and effectiveness of a remotely delivered, group-based lifestyle modification intervention (LMI) for women with gynecologic cancer and overweight or obesity in a real-world clinic. METHODS: …

other 2025
doi:10.1016/j.ygyno.2025.05.013 ·PMID:40482607

OBJECTIVE: Many epithelial ovarian cancer (EOC) risk factors relate to sex hormones. The association between these factors and the expression of androgen receptor (AR), estrogen receptor-α (ER), and progesterone receptor (PR) in tumors is u…

observational 2025
doi:10.1016/j.ygyno.2025.08.033 ·PMID:40934858

OBJECTIVES: To examine variation in physician adoption of opportunistic salpingectomy (OS) for patients undergoing tubal sterilization. STUDY DESIGN: Using the Premier Healthcare Database, we identified patients age 18-49 undergoing postpa…

observational 2025
doi:10.1016/j.ygyno.2025.05.008 ·PMID:40499207

OBJECTIVE: Previous results on the association between statin use and risk of ovarian cancer (OC) are inconsistent, warranting further investigation. This study aims to examine the association between statin use and risk of OC in a large st…

observational 2024
doi:10.1016/j.ygyno.2024.10.008 ·PMID:39396406

OBJECTIVE: To evaluate the disease course of patients with low grade endometrial stromal sarcoma (LG-ESS) and compare oncologic outcomes associated with hormonal therapy in primary and recurrent disease. METHODS: This is a retrospective st…

diagnostic-accuracy 2024
doi:10.1016/j.ygyno.2024.01.049 ·PMID:38335900

INTRODUCTION: It is unclear if sentinel node (SLN) mapping can replace pelvic- (PLD) and paraaortic lymphadenectomy (PALD) for high-risk endometrial cancer (EC). A diagnostically safe surgical algorithm, taking failed mapping cases into acc…

observational 2024
doi:10.1016/j.ygyno.2024.07.690 ·PMID:39128337

BACKGROUND: Individuals with germline BRCA1 and BRCA2 pathogenic variants (BRCA carriers) are at high risk of developing high grade serous ovarian carcinoma (HGSC). HGSC is predominantly driven by TP53 mutations, but mutations in this gene …

observational 2024
doi:10.1016/j.ygyno.2024.01.015 ·PMID:38246044

OBJECTIVES: Mesonephric (MA) and mesonephric-like (MLA) adenocarcinomas are rare cancers, and data on clinical behavior and response to therapy are limited. We sought to report molecular features, treatment, and outcomes of MA/MLA from a si…

observational 2024
doi:10.1016/j.ygyno.2024.08.010 ·PMID:39173565

OBJECTIVE: High-grade (HGOC) and low-grade ovarian carcinoma (LGOC) are distinct malignancies with different biological features, treatment paradigms, and life expectancies. However, differences in quality of life (QOL), sleep, and depressi…

diagnostic-accuracy 2024
doi:10.1016/j.ygyno.2024.08.008 ·PMID:39180961

OBJECTIVE: To determine whether a multimodal assay combining serum microRNA with protein biomarkers and metadata improves triage assessment of an adnexal mass. METHODS: Serum samples from 468 training subjects (191 cancer cases and 277 ben…

lab-animal 2023
doi:10.1016/j.ygyno.2023.03.020 ·PMID:37121178

OBJECTIVE: To demonstrate that shared antibody responses in endometriosis and endometriosis-associated ovarian cancer spontaneously antagonize malignant progression and can be leveraged to develop future immunotherapies. METHODS: B cells f…

nonrandomized-trial 2023
doi:10.1016/j.ygyno.2023.06.021 ·PMID:37418832

OBJECTIVE: Gynecologic cancers are traditionally managed according to their presumed site of origin, without regard to the underlying histologic subtype. Clear cell histology is associated with chemotherapy refractoriness and poor survival.…

other 2023
doi:10.1016/j.ygyno.2023.06.579 ·PMID:37478617

OBJECTIVES: To evaluate clinical, laboratory, and radiological variables from preoperative contrast-enhanced computed tomography (CECT) for their ability to distinguish ovarian clear cell carcinoma (OCCC) from non-OCCC and to develop a nomo…

rct 2023
doi:10.1016/j.ygyno.2023.05.001 ·PMID:37182434

OBJECTIVE: To compare the effects of levonorgestrel-intrauterine system (LNG-IUS) with or without oral megestrol acetate (MA) versus MA alone on fertility-preserving treatment in patients with atypical endometrial hyperplasia (AEH). METHOD…

observational 2023
doi:10.1016/j.ygyno.2023.10.013 ·PMID:37992548

OBJECTIVE: To assess the impact of short-term postoperative complications on oncologic outcomes for patients with epithelial ovarian cancer undergoing primary cytoreductive surgery (PCS) or interval cytoreductive surgery (ICS) with intestin…

observational 2023
doi:10.1016/j.ygyno.2022.10.018 ·PMID:36401943

OBJECTIVE: The presence of macroscopic residual disease after primary cytoreductive surgery (PCS) is an important factor influencing survival for patients with high-grade serous ovarian cancer (HGSC). More research is needed to identify fac…

nonrandomized-trial 2023
doi:10.1016/j.ygyno.2023.11.007 ·PMID:37980769

OBJECTIVE: Sistematic pelvic and para-aortic lymphadenectomy is part of the staging surgery for early-stage epithelial ovarian cancer, with no therapeutic value. The Mapping Sentinel Lymph Nodes In Early-Stage Ovarian Cancer (MELISA) trial …

nonrandomized-trial 2023
doi:10.1016/j.ygyno.2023.02.013 ·PMID:36893488

OBJECTIVE: The SENTIREC-endo study aims to investigate risks and benefits of a national protocolled adoption of sentinel lymph node (SLN) mapping in women with early-stage low-grade endometrial cancer (EC) with low- (LR) and intermediate-ri…

other 2022
doi:10.1016/j.ygyno.2022.02.021 ·PMID:35277280

OBJECTIVE: Black women suffer a higher mortality from endometrial cancer (EC) than White women. Potential biological causes for this disparity include a higher prevalence of obesity and more lethal histologic/molecular subtypes. We hypothes…